
Opinion|Videos|September 30, 2024
Therapeutic Combination Therapies for Metastatic Prostate Cancer
Author(s)Fred Saad, CQ, MD, FRCS, FCAHS
Fred Saad, CQ, MD, FRCS, FCAHS, discusses how combining therapies like androgen receptor–targeted agents, androgen deprivation therapy, and docetaxel can potentially improve outcomes for metastatic prostate cancer patients, with treatment selection influenced by factors such as disease volume and risk level.
Advertisement
Video Player is loading.
Episodes in this series
The above content is prompted by the following:
- Discuss some therapeutic combinations for metastatic prostate cancer.
- What is the general rationale for using combination therapy (eg, androgen receptor–targeted agent and/or an androgen deprivation therapy with docetaxel)?
- How do disease volume and level of disease risk affect selection of therapy?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial launches of neuromodulation therapy for erectile dysfunction after radical prostatectomy
2
PROSTOX ultra launches on US market following new data presented at ASTRO 2025
3
Published data show benefit of niraparib with AAP in HRR-deficient mCSPC
4
Rectal diazepam eases instillation of nadofaragene firadenovec in NMIBC
5